Needs Assessment of Knowledge, Beliefs, & Attitudes of Patients With

Status Recruiting

Clinical Trial Summary

Gene therapy is a paradigm-shifting treatment for hemophilia B patients, particularly in resource-limited countries where factor availability remains low. Transparent and culturally sensitive communication around gene therapy is vital to the success of a high-quality consenting process. Current literature on knowledge, beliefs and attitudes about gene therapy in resource-limited countries is inadequate. In addition, few educational resources to explain basic gene therapy concepts exist in languages other than English. This study aims to address these gaps in knowledge and aid for the development of educational resources to assist the informed consent processes for gene therapy in resource-limited countries. Primary Objective: To assess baseline knowledge, beliefs, and attitudes about gene therapy held by hemophilia B patients globally Secondary Objectives: 1. To explore healthcare workers' (i.e., physicians, nurses, social workers, educators/academic coordinators) perspectives regarding the education needs of hemophilia B patients globally 2. To explore healthcare workers beliefs and attitudes about gene therapy 3. To identify preferences of patients with hemophilia B and their healthcare workers on how/by what method or pathway educational content should be provided.

Clinical Trial Description

This prospective cohort study will use qualitative methods, specifically semi structured interviews to evaluate knowledge, beliefs, and attitude about gene therapy in patients 12 years and older with a diagnosis of moderate and severe hemophilia B (≤2% FIX activity only), caregivers/parents and healthcare workers who care for them at St. Jude and other global countries. Participants will be interviewed virtually using an online video-conferencing platform, phone or in person. Interviews will be performed by experienced qualitative interviewers in the official language of each participating site. Interviews will last approximately 45-60 minutes and will be performed only once. All interviews will be audio recorded and obtained information will be analyzed using semantic content analysis to identify common themes. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05044845
Study type	Observational
Source	St. Jude Children's Research Hospital
Contact	Nidhi Bhatt, MD
Phone	901-426-6982
Email	binformedstudy@stjude.org
Status	Recruiting
Phase
Start date	January 18, 2022
Completion date	January 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04072237` - Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia	Phase 1
Completed	`NCT02199717` - An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia	N/A
Completed	`NCT01662531` - A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B	Phase 3
Completed	`NCT01335061` - Study To Compare On-Demand Treatment To A Prophylaxis Regimen Of BeneFIX In Subjects With Moderately Severe to Severe Hemophilia B	Phase 3
Completed	`NCT01217255` - Comparing the Burden of Illness of Hemophilia in the Developing and the Developed World
Completed	`NCT00037557` - Study Evaluating rFIX; BeneFIX in Severe Hemophilia B	Phase 3
Completed	`NCT02554773` - An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B	Phase 1/Phase 2
Terminated	`NCT02807753` - The Hemophilia Ultrasound Project
Active, not recruiting	`NCT03901755` - An International Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B
Not yet recruiting	`NCT05980377` - Patterns of Hemophilia Care in Assiut Children Patients
Recruiting	`NCT05687474` - Baby Detect : Genomic Newborn Screening
Terminated	`NCT03248141` - Understanding Hemophilia A and B Drug Dosage Administration Patterns
Terminated	`NCT01460147` - Osteoporosis and MRI Study in Hemophilia	N/A
Completed	`NCT03818529` - ATHN 8: Previously Untreated Patients (PUPs) Matter Study
Completed	`NCT02571569` - A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors	Phase 1
Terminated	`NCT01620801` - Hemophilia B Gene Therapy With AAV8 Vector	Phase 1
Completed	`NCT01233440` - Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein in Subjects With Hemophilia B	Phase 1
Active, not recruiting	`NCT04135300` - Gene Therapy for Chinese Hemophilia B	N/A
Enrolling by invitation	`NCT03655223` - Early Check: Expanded Screening in Newborns
Terminated	`NCT00947193` - Study of Ataluren (PTC124) in Hemophilia A and B	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Needs Assessment of Knowledge, Beliefs, and Attitudes of Patients With Hemophilia B About Gene Therapy

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms